Provided by Tiger Trade Technology Pte. Ltd.

Korro Bio, Inc.

10.16
-0.4200-3.97%
Post-market: 9.96-0.2000-1.97%17:09 EDT
Volume:133.51K
Turnover:1.38M
Market Cap:149.61M
PE:-1.03
High:10.78
Open:10.60
Low:10.13
Close:10.58
52wk High:55.89
52wk Low:5.20
Shares:14.73M
Float Shares:10.53M
Volume Ratio:0.91
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.8800
EPS(LYR):-12.4806
ROE:-97.69%
ROA:-27.95%
PB:1.45
PE(LYR):-0.81

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Korro Bio (KRRO), Electrocore (ECOR) and BioLife Solutions (BLFS)

TIPRANKS
·
Aug 07

Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate

Benzinga Earnings
·
Aug 06

Korro Bio Publishes Corporate Deck Outlining RNA-Editing Pipeline for Hyperammonemia and Alpha-1 Antitrypsin Deficiency

Reuters
·
Aug 06

Korro Bio Q2 FY26 Net Loss Narrows to USD 18.92 Million; Revenue Posts no Collaboration Revenue

Reuters
·
Aug 06

Korro Bio, - Q2 2026 Net Loss $18.90 Mln

THOMSON REUTERS
·
Aug 06

Korro Bio Grants Stock Options for 23,000 Shares to Seven New Hires Under Inducement Plan

Reuters
·
Jul 11

Korro Bio Director Jean Francois Formela Reports Disposal of Common Shares Worth $1.53 Million

Reuters
·
Jul 08

Korro Bio Director Jean Francois Formela Disposes of USD 2.47 Million in Common Shares

Reuters
·
Jun 25

Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?

Simply Wall St.
·
Jun 16

Korro Bio shareholders elect Bermingham, Meyers as Class I directors at annual meeting

Reuters
·
Jun 12

Korro Bio director Jean Francois Formela disposes of 2,860 common shares worth $39,897‬

Reuters
·
Jun 02

Korro Bio initiated with an Outperform at LifeSci Capital

TIPRANKS
·
May 29

Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)

TIPRANKS
·
May 28

Korro Bio CEO Ram Aiyar to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Korro Bio (KRRO) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Korro Bio selects KRRO-111 as development candidate

TIPRANKS
·
May 19

Korro Bio Advances KRRO-111 for Alpha-1 Deficiency

TIPRANKS
·
May 19

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire
·
May 19

Korro Bio, Inc. : H.c. Wainwright Cuts Target Price to $15 From $20

THOMSON REUTERS
·
May 19

Korro Bio Initiated at Buy by Citigroup

Dow Jones
·
May 18